TSCAN THERAPEUTICS, INC. Stock-Based Compensation
TSCAN THERAPEUTICS, INC. (TCRX) reported Stock-Based Compensation of $4.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.36M, a 27.99% decline year-over-year.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.46M, a 27.80% decline year-over-year.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.01M, a 26.01% decline year-over-year.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.01M, a 19.34% increase year-over-year.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $11.71M, a 22.59% increase from fiscal 2024.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $9.55M, a 83.35% increase from fiscal 2023.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $5.21M, a 14.44% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $4.55M, a 80.88% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.82M 10-Q · filed 2026-08-12 | $6.83M derived: sum of 3 quarters · filed 2026-08-12 | $9.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.46M 10-Q · filed 2026-05-06 | $4.47M derived: sum of 2 quarters · filed 2026-05-06 | $7.48M derived: sum of 3 quarters · filed 2026-05-06 | $10.76M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.02M derived: sum of 2 quarters · filed 2026-03-04 | $8.29M derived: sum of 3 quarters · filed 2026-08-12 | $11.71M 10-K · filed 2026-03-04 |
| 2025-09-30 | $3.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.28M derived: sum of 2 quarters · filed 2026-08-12 | $9.70M 10-Q · filed 2025-11-12 | $12.41M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.69M 10-Q · filed 2026-08-12 | $9.40M derived: sum of 3 quarters · filed 2026-08-12 | $11.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.41M 10-Q · filed 2026-05-06 | $6.13M derived: sum of 2 quarters · filed 2026-05-06 | $8.65M derived: sum of 3 quarters · filed 2026-05-06 | $10.98M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.24M derived: sum of 2 quarters · filed 2026-03-04 | $7.57M derived: sum of 3 quarters · filed 2026-03-04 | $9.55M 10-K · filed 2026-03-04 |
| 2024-09-30 | $2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.85M derived: sum of 2 quarters · filed 2025-11-12 | $6.83M 10-Q · filed 2025-11-12 | $8.34M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $4.31M 10-Q · filed 2025-08-12 | $5.81M derived: sum of 3 quarters · filed 2025-08-12 | $7.15M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.98M 10-Q · filed 2025-05-06 | $3.48M derived: sum of 2 quarters · filed 2025-05-06 | $4.83M derived: sum of 3 quarters · filed 2025-05-06 | $6.04M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $2.84M derived: sum of 2 quarters · filed 2025-03-05 | $4.06M derived: sum of 3 quarters · filed 2025-03-05 | $5.21M 10-K · filed 2025-03-05 |
| 2023-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.56M derived: sum of 2 quarters · filed 2024-11-12 | $3.71M 10-Q · filed 2024-11-12 | $5.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.37M 10-Q · filed 2024-08-12 | $3.66M derived: sum of 3 quarters · filed 2024-08-12 | $4.91M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.15M 10-Q · filed 2024-05-13 | $2.44M derived: sum of 2 quarters · filed 2024-05-13 | $3.69M derived: sum of 3 quarters · filed 2024-05-13 | $4.71M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $2.54M derived: sum of 2 quarters · filed 2024-03-06 | $3.57M derived: sum of 3 quarters · filed 2024-03-06 | $4.55M 10-K · filed 2024-03-06 |
| 2022-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.27M derived: sum of 2 quarters · filed 2023-11-09 | $3.25M 10-Q · filed 2023-11-09 | $4.04M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.01M 10-Q · filed 2023-08-10 | $2.79M derived: sum of 3 quarters · filed 2023-08-10 | $3.68M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $984.00K 10-Q · filed 2023-05-10 | $1.77M derived: sum of 2 quarters · filed 2023-05-10 | $2.65M derived: sum of 3 quarters · filed 2023-05-10 | $3.16M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.67M derived: sum of 2 quarters · filed 2023-03-08 | $2.17M derived: sum of 3 quarters · filed 2023-03-08 | $2.52M 10-K · filed 2023-03-08 |
| 2021-09-30 | $885.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.39M derived: sum of 2 quarters · filed 2022-11-09 | $1.73M 10-Q · filed 2022-11-09 | $1.88M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $503.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $847.00K 10-Q · filed 2022-08-10 | $997.00K derived: sum of 3 quarters · filed 2022-08-10 | $1.13M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $344.00K 10-Q · filed 2022-05-12 | $494.00K derived: sum of 2 quarters · filed 2022-05-12 | $623.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $279.00K derived: sum of 2 quarters · filed 2022-03-09 | $515.00K 10-K · filed 2022-03-09 | |
| 2020-09-30 | $129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $365.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $236.00K 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |